Maximize Our Pipeline
NuPathe actively seeks relationships to maximize the commercial potential for our existing pipeline through partnerships in the U.S. and territories throughout the world. We are very interested in advancing our product candidates through development to commercialization as rapidly and efficiently as possible.
We welcome inquiries regarding partnerships for:
- Commercialization opportunities in the U.S. and worldwide for Zecuity.
- NP201, a long-acting biodegradable implant for the treatment of Parkinson’s disease, addressing the needs of this significant global population of underserved patients.
- NP202, a long-acting biodegradable implant for the treatment of schizophrenia and bipolar disorder, addressing the serious and long-standing problem of medication non-compliance.
Leverage Our Technology Platforms
NuPathe is interested in collaborations leveraging our drug delivery platforms.
SmartRelief Active Transdermal Delivery
NuPathe’s transformative SmartRelief technology positions the company to capitalize on the rapidly expanding global transdermal market (forecasted to increase from $21.5 to $31.5 billion by 2015), by potentially opening entirely new classes of medications for delivery through the skin, including proteins/peptides, small molecules and nucleic acids. We seek collaborations to leverage this technology for additional franchise opportunities with significant market potential.
LAD (Long-Acting Delivery) Biodegradable Implant
LAD, a biodegradable implant used to deliver an active drug, is designed to improve the control, consistency and convenience of medication delivery. Based on studies to date, we believe LAD has the potential to treat patients for up to six months with a single dose of a therapy depending on the active drug. As a result, we believe the consistent and continuous drug delivery offered by LAD has the potential to improve medication efficacy, compliance and incidence of drug-related adverse events. We seek collaborations to leverage this technology for development.
NuPathe exclusively owns all worldwide rights to the migraine patch, with issued patents through April 2029.